Eckert & Ziegler SE (STU:EUZ) ROCE %: 16.94% (As of Mar. 2026)


STU:EUZ Eckert & Ziegler SE STU:EUZ
98 GF Score
Price €15.13
GF Value €16.06
Valuation Fairly Valued
View Full Analysis

What is Eckert & Ziegler SE ROCE %?

Eckert & Ziegler SE STU:EUZ -0.59% 98 ROCE % is 16.94% as of Mar. 2026. GuruFocus rates STU:EUZ with a GF Score™ of 98/100 and a GF Value™ of €16.06 (Fairly Valued).

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Eckert & Ziegler SE's annualized ROCE % for the quarter that ended in Mar. 2026 was 16.94%.

Eckert & Ziegler SE  (STU:EUZ) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Eckert & Ziegler SE ROCE % Related Terms

Eckert & Ziegler SE ROCE % Historical Data

* Premium members only.

The historical data trend for Eckert & Ziegler SE's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Eckert & Ziegler SE ROCE % Chart

Eckert & Ziegler SE Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
ROCE %
Get a 7-Day Free Trial Premium Member Only Premium Member Only 18.04 14.74 13.11 17.11 20.43

Eckert & Ziegler SE Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
ROCE % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 16.84 20.47 16.58 29.28 16.94
STU:EUZ
98GF Score
Eckert & Ziegler SE STU:EUZ
ROCE % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Eckert & Ziegler SE ROCE % Calculation

Eckert & Ziegler SE's annualized ROCE % for the fiscal year that ended in Dec. 2025 is calculated as:

ROCE %=EBIT/( (Capital Employed+Capital Employed)/ count )
(A: Dec. 2025 )  (A: Dec. 2024 )(A: Dec. 2025 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(A: Dec. 2025 )  (A: Dec. 2024 )(A: Dec. 2025 )
=77.249/( ( (442.396 - 72.219) + (457.926 - 71.779) )/ 2 )
=77.249/( (370.177+386.147)/ 2 )
=77.249/378.162
=20.43 %

Eckert & Ziegler SE's ROCE % of for the quarter that ended in Mar. 2026 is calculated as:

ROCE %=EBIT (1)/( (Capital Employed+Capital Employed)/ count )
(Q: Mar. 2026 )  (Q: Dec. 2025 )(Q: Mar. 2026 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(Q: Mar. 2026 )  (Q: Dec. 2025 )(Q: Mar. 2026 )
=66.716/( ( (457.926 - 71.779) + (476.529 - 74.86) )/ 2 )
=66.716/( ( 386.147 + 401.669 )/ 2 )
=66.716/393.908
=16.94 %

(1) Note: The EBIT data used here is four times the quarterly (Mar. 2026) EBIT data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about ROCE % →
What does a ROCE % of 16.94% mean?
Eckert & Ziegler SE (STU:EUZ) has a ROCE % of 16.94% as of Mar. 2026.
Is Eckert & Ziegler SE's ROCE % too high?
Eckert & Ziegler SE's current ROCE % is 16.94%. The Medical Devices & Instruments industry median ROCE % is 2.23. Eckert & Ziegler SE's value of 16.94% is 659.6% above this industry median. Overall, Eckert & Ziegler SE has a GF Score™ of 98/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Eckert & Ziegler SE's ROCE % compare to ABT and SYK?
Eckert & Ziegler SE's ROCE % of 16.94% can be compared against companies in the Medical Devices & Instruments industry. The industry median ROCE % is 2.23. Eckert & Ziegler SE's value of 16.94% is 659.6% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROCE % for a Medical Devices & Instruments company?
The median ROCE % among Medical Devices & Instruments companies is 2.23, based on 814 companies in the industry. Companies in the top quartile (top 25%) have a ROCE % significantly above this median, while those in the bottom quartile fall well below. However, ROCE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Eckert & Ziegler SE's current ROCE % of 16.94% is 659.6% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROCE % mean?
A high ROCE % can signal that a stock is expensive relative to its fundamentals. For the Medical Devices & Instruments industry, the median ROCE % is 2.23 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Eckert & Ziegler SE's current ROCE % is 16.94%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Eckert & Ziegler SE stock overvalued right now?
Based on GuruFocus' analysis, Eckert & Ziegler SE (STU:EUZ) is currently considered Fairly Valued. The stock's GF Value™ is €16.06, compared to a current price of €15.13 — trading 5.8% below its estimated fair value. The current ROCE % is 16.94% and 659.6% above the Medical Devices & Instruments industry median of 2.23. Eckert & Ziegler SE's overall GF Score™ is 98/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROCE % calculated?
ROCE % is calculated from a company's financial statements. For Eckert & Ziegler SE (STU:EUZ), the current ROCE % is 16.94% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Eckert & Ziegler SE (STU:EUZ) Overvalued in 2026?

Based on GuruFocus' analysis, Eckert & Ziegler SE stock appears to be undervalued. The current stock price of €15.13 is trading 5.8% below its estimated GF Value™ of €16.06. GuruFocus considers Eckert & Ziegler SE to be Fairly Valued.

Key valuation signals for STU:EUZ:

  • ROCE %: 16.94%
  • GF Value™: €16.06 vs. price of €15.13 (5.8% below fair value)
  • GF Score™: 98/100
  • Industry Position: 659.6% above the Medical Devices & Instruments median

No single metric tells the full story. See the STU:EUZ stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Eckert & Ziegler SE Business Description

Address Robert-Rossle-Street 10, Berlin, BB, DEU, 13125
Eckert & Ziegler SE is a holding company with specialised in the processing of radioisotopes and the development, production and sale of isotope technology components, radiopharmaceuticals and related products. It is an international manufacturer of isotope technology components for medical, scientific, and industrial applications. The group's products are mainly used in cancer therapy, nuclear imaging, and industrial metrology. The company's segments are Medical, Isotope Products, and Other. The majority of revenue comes from Medical segment which provides pharmaceutical-quality radioactive ingredients and markets products for the treatment and diagnosis of cancers. Geographically, the company generates a majority of its revenue from Europe and then North America, Asia/Pacific, and other.
98GF Score

Get the complete analysis for STU:EUZ

ROCE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€15.13
Price
€16.06
GF Value